Acute Medium Chain Triglycerides (MCT) Intake in Young and Older Participants
NCT ID: NCT03830268
Last Updated: 2020-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2017-06-02
2019-06-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ketone Levels Achieved After Medium Chain Triglyceride (MCT) Oil
NCT04389983
Determination of the Optimal Nutrient Mix to Acutely Increase Plasma Ketones
NCT06511206
Effect of Butter & MCT Oil on Lipoproteins - A RCT
NCT02611102
Isolating & Exploiting the Mechanisms That Link Breakfast to Human Health - Acute
NCT03866720
Effects of Medium-Chain Triglycerides on Chylomicron Secretion and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With Dyslipidemia Associated With the Metabolic Syndrome
NCT01806142
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MCT intake in young participants
Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in young participants.
Interventions:
1. No MCT intake with breakfast, no lunch (i.e. CTL)
2. No MCT intake with lunch, no breakfast (i.e CTL inverted)
3. 10g of Betaquik with breakfast, no lunch (i.e BQ10)
4. 20g of Betaquik with breakfast, no lunch (i.e BQ20)
5. 10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)
6. 10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)
No MCT intake with breakfast, no lunch
Water given with a regular standardize breakfast and water given at noon without lunch.
No MCT intake with lunch, no breakfast
Water given in the beginning of the metabolic study day without breakfast and water given at noon with a regular standardize lunch.
10g of Betaquik
BQ10 given with a regular standardize breakfast and BQ10 given at noon without lunch.
10g of Betaquik with low-carbs breakfast
BQ10 given with a low-carbs standardize breakfast and BQ10 given at noon without lunch.
20g of Betaquik
BQ20 given with a regular standardize breakfast and BQ20 given at noon without lunch.
10g of Betaquik with lunch, no breakfast
BQ10 given in the beginning of the metabolic study day without breakfast and BQ10 given at noon with a regular standardize lunch.
MCT intake in older participants
Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in older participants.
Interventions:
1. No MCT intake with breakfast, no lunch (i.e. CTL)
2. No MCT intake with lunch, no breakfast (i.e CTL inverted)
3. 10g of Betaquik with breakfast, no lunch (i.e BQ10)
4. 20g of Betaquik with breakfast, no lunch (i.e BQ20)
5. 10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)
6. 10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)
10g of Betaquik
BQ10 given with a regular standardize breakfast and BQ10 given at noon without lunch.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No MCT intake with breakfast, no lunch
Water given with a regular standardize breakfast and water given at noon without lunch.
No MCT intake with lunch, no breakfast
Water given in the beginning of the metabolic study day without breakfast and water given at noon with a regular standardize lunch.
10g of Betaquik
BQ10 given with a regular standardize breakfast and BQ10 given at noon without lunch.
10g of Betaquik with low-carbs breakfast
BQ10 given with a low-carbs standardize breakfast and BQ10 given at noon without lunch.
20g of Betaquik
BQ20 given with a regular standardize breakfast and BQ20 given at noon without lunch.
10g of Betaquik with lunch, no breakfast
BQ10 given in the beginning of the metabolic study day without breakfast and BQ10 given at noon with a regular standardize lunch.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men and women
Exclusion Criteria
* diabetes (fasting glucose \>7.0 mmol/l and glycated hemoglobin \>6.9%)
* strenuous aerobic exercise more than three times a week
* untreated hypertension, dyslipidemia, and abnormal renal, liver, heart or thyroid function
* under medication known to affect triglycerides and carbohydrates metabolism (i.e. diuretics, beta-blockers, steroids, insulin sensitizing)
20 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Université de Sherbrooke
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rearsh Centre on Aging
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cunnane SC, Courchesne-Loyer A, St-Pierre V, Vandenberghe C, Pierotti T, Fortier M, Croteau E, Castellano CA. Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer's disease. Ann N Y Acad Sci. 2016 Mar;1367(1):12-20. doi: 10.1111/nyas.12999. Epub 2016 Jan 14.
Croteau E, Castellano CA, Fortier M, Bocti C, Fulop T, Paquet N, Cunnane SC. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease. Exp Gerontol. 2018 Jul 1;107:18-26. doi: 10.1016/j.exger.2017.07.004. Epub 2017 Jul 12.
Courchesne-Loyer A, Croteau E, Castellano CA, St-Pierre V, Hennebelle M, Cunnane SC. Inverse relationship between brain glucose and ketone metabolism in adults during short-term moderate dietary ketosis: A dual tracer quantitative positron emission tomography study. J Cereb Blood Flow Metab. 2017 Jul;37(7):2485-2493. doi: 10.1177/0271678X16669366. Epub 2016 Jan 1.
Courchesne-Loyer A, Fortier M, Tremblay-Mercier J, Chouinard-Watkins R, Roy M, Nugent S, Castellano CA, Cunnane SC. Stimulation of mild, sustained ketonemia by medium-chain triacylglycerols in healthy humans: estimated potential contribution to brain energy metabolism. Nutrition. 2013 Apr;29(4):635-40. doi: 10.1016/j.nut.2012.09.009. Epub 2012 Dec 28.
Castellano CA, Nugent S, Paquet N, Tremblay S, Bocti C, Lacombe G, Imbeault H, Turcotte E, Fulop T, Cunnane SC. Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer's disease dementia. J Alzheimers Dis. 2015;43(4):1343-53. doi: 10.3233/JAD-141074.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-714
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.